Private philanthropy has been the driving force behind many of the most promising breakthroughs in treating leukemia, lymphoma and myeloma because these blood cancers are considered to be "orphan diseases" with limited commercial profit potential. Every dollar that The Leukemia & Lymphoma Society (LLS) invests in research worldwide comes from charitable contributions.
And because developing new treatments for blood cancers is an ambitious and complex process, the best time to invest is now.
Major gift commitments are invited for cutting-edge research, patient services and professional education initiatives. When you donate $10,000 or more, you can invest in a disease-specific research portfolio.
Get More Information
Contact Richard Schneyer, Vice President of Development, at email@example.com or (914) 821-8978.